Litcius/Paper detail

Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies

Haiqing Jia, Lei Jiang, Xiaoyu Shen, Huinan Ye, Xinguang Li, Liwei Zhang, Yanyan Hu, Dandan Song, Hui Jia, Zhe Wang

2025Molecular Cancer23 citationsDOIOpen Access PDF

Abstract

Immunotherapies, particularly immune checkpoint inhibitors (ICIs), have revolutionized cancer clinical management, but low response rates and treatment resistance remain challenging. Protein post-translational modifications (PTMs) are critical for governing protein expression, localization, functions, and interactions with other cellular molecules, which notably build up the diversity and complexity of the proteome. A growing body of evidence supports that PTMs influence immunotherapy efficacy and outcomes by post-translationally modulating the expression and functions of immune checkpoints. Therefore, understanding the PTM mechanisms that govern immune checkpoints is paramount for developing novel treatment strategies to improve immunotherapy efficacy and overcome resistance. This review provides an overview of the current comprehension of the regulatory mechanisms by which PTMs (glycosylation, phosphorylation, ubiquitination, acetylation, succinylation, palmitoylation, lactylation, O-GlcNAcylation, UFMylation, and neddylation) modulate immune checkpoints to unveil potential therapeutic targets. Moreover, this review discusses the potential of therapeutic strategies targeting PTMs of immune checkpoints, providing insights into the combination treatment with ICIs in maximizing the benefits of immunotherapy and overcoming resistance.

Topics & Concepts

BiologyCancerImmune systemComputational biologyCancer researchPosttranslational modificationBioinformaticsImmunologyGeneticsBiochemistryEnzymeCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCAR-T cell therapy research
Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies | Litcius